Formats
  1. Journal Article (66975)
  2. Meeting Abstract (33621)
  3. Book Section (5116)
  4. Review (3781)
  5. Editorial (2185)
  6. Conference Paper (1531)
  7. Correspondence (669)
  8. Guidelines (666)
  9. Research Letter (554)
  10. Book Whole (345)
  11. Miscellaneous (340)
Groups
  1. Department of Medicine (39123)
  2. GSK Faculty (22500)
  3. Solid Tumor Oncology Division (22113)
  4. Surgery (21304)
  5. Survivorship Research (15795)
  6. Sloan Kettering Institute Faculty (15665)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1053)

More People

Years
  1. 2026 (1)
  2. 2025 (2315)
  3. 2024 (5382)
  4. 2023 (5808)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8596)
  2. Blood (4954)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2614)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13867)
  2. American Society of Clinical Oncology (9180)
  3. Springer (7199)
  4. Nature Publishing Group (6392)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5526)

More Publishers

Results (115783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
    Meeting Abstract

    Odintsov, I.; Liu, A.; Khodos, I.; Chang, Q.; Giuliano, C.; Mattar, M.; Vojnic, M.; Bonifacio, A.; De Stanchina, E.; Lovati, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Preliminary results from FLAGSHP-1: A phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    Meeting Abstract

    McKean, M.; Barve, M.; Hong, D.; Parikh, A.; Rosen, E.; Yang, J.; Picard, R.; Yi, J.; Brail, L.; Vecchio, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742
    Meeting Abstract

    Saffran, D.; Poon, E.; Ibanez, G.; Nakashima, J.; Amara, S. N. A.; Noe, C.; Hood, T.; Kumar, P.; DiMartino, J.; Dela Cruz, F.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • A radiohapten capture system for CAR T cells that tracks them in vivo and improves efficacy
    Meeting Abstract

    Kurtz, K.; Eibler, L.; Dacek, M.; Carter, L.; Cheal, S.; Veach, D.; Qureshy, S.; Han, J.; Reynaud, E.; Verma, S.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors
    Meeting Abstract

    Drilon, A.; Besse, B.; Camidge, D. R.; Ou, S. H. I.; Gadgeel, S. M.; Johnson, M. L.; Calles, A.; de Miguel, M. J.; Spira, A. I.; Felip, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Growth factor signaling and kinase inhibitors regulate oncogenesis in desmoid fibromatosis by modulating activity of the beta-catenin transcription target ABL1
    Meeting Abstract

    Hu, J.; Villano, A.; O'Connor, R.; Rozenberg, Y.; Venkatesh, A.; Gounder, M.; Socci, N.; Singer, S.; Hameed, M.; Crago, A. M.
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
    Meeting Abstract

    Zain, D. R.; Iyer, S. P.; Sica, R. A.; Ho, P. J.; Hu, B.; Prica, A.; Weng, W. K.; Kim, Y. H.; Khodadoust, M. S.; Palomba, M. L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30
    Meeting Abstract

    Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G.; Vogl, A.; Schumacher, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Cho, B. C.; Lin, J.; Camidge, D. R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K. H.; Kim, S. W.; Kao, S.; Diadziuskzko, R.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Predictors of outcomes in hematopoietic cell transplantation for fanconi anemia: A multicenter analysis
    Meeting Abstract

    Cancio, M.; Troullioud, A.; Elizabeth, K.; de Witte, M.; Smiers, F.; Bresters, D.; Boelens, J. J.; Bierings, M.; Smetsers, S.
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save